This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Julian Adams, Ph.D., Of Infinity Pharmaceuticals Named Corporate Chair For The Leukemia & Lymphoma Society’s Light The Night Walk

The Massachusetts chapter of The Leukemia & Lymphoma Society (LLS) named Julian Adams, Ph.D., of Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) as corporate chair of its 2014 Light The Night ® Walk, LLS’s annual fundraising event for cancer research and patient services. Dr. Adams serves as president, research and development, at Infinity and is responsible for the full spectrum of the company’s drug discovery, preclinical and clinical development strategy and regulatory affairs activities.

LLS holds walks each fall in approximately 200 communities across the United States and Canada. Participants at the walks carry illuminated balloons – white for survivors, red for supporters, and gold to remember those who have died – to honor and commemorate lives touched by blood cancer.

“Forming Light The Night Walk teams is a great way to build team spirit among employees, raise awareness about the need for more blood cancer therapies and recognize those who continue to be affected by these diseases,” said Dr. Adams. “These same objectives – and our desire to continue our support of LLS – led us to recently launch Infinity Pharmaceuticals’ “ Sparks of Inspiration” campaign. I am honored to serve as the chair of the 2014 Light The Night Walk and look forward to helping more local businesses and corporations get their employees involved.”

Prior to joining Infinity in 2003, Dr. Adams served as senior vice president, drug discovery and development at Millennium Pharmaceuticals. In this capacity, he held global responsibility for multiple drug discovery programs, including the successful discovery and development of Velcade ® (bortezomib), a proteasome inhibitor for two different blood cancers: multiple myeloma and relapsed mantle cell lymphoma. He previously held senior management positions with organizations such as LeukoSite, ProScript, Inc. and Boehringer Ingelheim, where he successfully discovered the drug Viramune ® (nevirapine) for HIV. Dr. Adams’ awards include the 2012 Warren Alpert Foundation Prize for his role in the discovery and development of bortezomib, the 2012 C. Chester Stock Award Lectureship from Memorial Sloan-Kettering Cancer Center, and the 2001 Ribbon of Hope Award for Velcade ® from the International Myeloma Foundation.

The funds raised through corporate and individual contributions during the Light The Night ® Walk help to find cures and better therapies for leukemia, lymphoma, Hodgkin disease and myeloma. Donations also provide information, education and support for patients and their families.

“Light The Night Walk gives hope to patients and their families and lets them know they are not alone in their battle against cancer,” said Sharon Klein, executive director of the Massachusetts chapter of the LLS.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,232.02 -53.72 -0.29%
S&P 500 2,126.06 -4.76 -0.22%
NASDAQ 5,089.3620 -1.4320 -0.03%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs